



Isodiol International Inc. Increases Size of Non-Brokered Offering and Retains Clarus Securities as Financial Advisor

Isodiol Increases Size of Private Placement to \$18 Million With the Upsize Led by Anson Funds



May 04, 2018 18:37 ET | Source: Isodiol - <https://globenewswire.com/news-release/2018/05/04/1497101/0/en/Isodiol-International-Inc-Increases-Size-of-Non-Brokered-Offering-and-Retains-Clarus-Securities-as-Financial-Advisor.html>

VANCOUVER, British Columbia, May 04, 2018 (GLOBE NEWSWIRE) -- **Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the "Company" or "Isodiol")**, a global CBD innovator specializing in the development of pharmaceutical, health, and wellness products and now supporting the pharmaceutical industry at large with its recently approved CBD as an Active Pharmaceutical Ingredient, is pleased to announce that it will be increasing the size of its previously announced private placement from \$10,000,000 to \$18,000,000 (the "Private Placement" or the "Offering"). The Company has also engaged Clarus Securities Inc. as financial advisor in connection with the Offering.

The additional investment will be led by Anson Funds, a privately held alternative asset manager. The proceeds from the Offering will be used to fund the recently announced global expansion into China and the UK. The Offering is subject to customary closing conditions and is expected to close on or about May 11th, 2018.

For more information on Isodiol, please visit www.isodiol.com

About Isodiol International Inc.

Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of CBD consumer products.

Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99% + pure, pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products and most recently received approval as having the first CBD designated as an Active Pharmaceutical Ingredient as was announced [April 26, 2018](#).

Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytochemical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.

Join Us On Facebook: <https://www.facebook.com/isodiol/>

Twitter: [@isodiol](#)

ON BEHALF OF THE BOARD

Marcos Agramont, CEO & Director

INVESTOR RELATIONS:

Ir@isodiol.com

www.isodiol.com